What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.35 and its highest was $7.32 in the past 12 months.
What is Molecular Partners’s market cap?
Currently, no data Available
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Aug 26, 2024 which is in 150 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Mar 14, 2024. The company reported -$1.109 earnings per share for the quarter, the consensus estimate of -$1.109 by $0.
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 36,368,900 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$1.109 in its last earnings report, expectations of -$1.109. Following the earnings report the stock price went up 2.591%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.